825 related articles for article (PubMed ID: 31548600)
21. Expression of costimulatory and inhibitory receptors in FoxP3
Toker A; Ohashi PS
Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic remodeling of the immune landscape in cancer: therapeutic hurdles and opportunities.
Tien FM; Lu HH; Lin SY; Tsai HC
J Biomed Sci; 2023 Jan; 30(1):3. PubMed ID: 36627707
[TBL] [Abstract][Full Text] [Related]
23. Turning Cold into Hot: Firing up the Tumor Microenvironment.
Duan Q; Zhang H; Zheng J; Zhang L
Trends Cancer; 2020 Jul; 6(7):605-618. PubMed ID: 32610070
[TBL] [Abstract][Full Text] [Related]
24. Genetic and epigenetic strategies for advancing ovarian cancer immunotherapy.
Cho Y; Milane L; Amiji MM
Expert Opin Biol Ther; 2019 Jun; 19(6):547-560. PubMed ID: 30933545
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic regulation of immune checkpoints: another target for cancer immunotherapy?
Ali MA; Matboli M; Tarek M; Reda M; Kamal KM; Nouh M; Ashry AM; El-Bab AF; Mesalam HA; Shafei AE; Abdel-Rahman O
Immunotherapy; 2017 Jan; 9(1):99-108. PubMed ID: 28000527
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.
Terranova-Barberio M; Thomas S; Munster PN
Immunotherapy; 2016 Jun; 8(6):705-19. PubMed ID: 27197539
[TBL] [Abstract][Full Text] [Related]
27. Advances and Challenges in Interventional Immuno-Oncology Locoregional Therapies.
Altun I; Demirlenk YM; Atar D; Cevik E; Gunduz S; Albadawi H; Oklu R
J Vasc Interv Radiol; 2024 Feb; 35(2):164-172. PubMed ID: 38272636
[TBL] [Abstract][Full Text] [Related]
28. Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy.
Singh V; Nandi S; Ghosh A; Adhikary S; Mukherjee S; Roy S; Das C
Cancer Metastasis Rev; 2024 Mar; 43(1):175-195. PubMed ID: 38233727
[TBL] [Abstract][Full Text] [Related]
29. Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy.
Wei G; Zhang H; Zhao H; Wang J; Wu N; Li L; Wu J; Zhang D
Cancer Lett; 2021 Jul; 511():68-76. PubMed ID: 33957184
[TBL] [Abstract][Full Text] [Related]
30. CIMT 2017: Anniversary symposium - Report on the 15th CIMT Annual Meeting of the Association for Cancer Immunotherapy.
Kranz LM; Beck JD; Grunwitz C; Hotz C; Vormehr M; Diken M
Hum Vaccin Immunother; 2017 Oct; 13(10):2272-2279. PubMed ID: 28846471
[No Abstract] [Full Text] [Related]
31. Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.
Park J; Thomas S; Munster PN
Epigenomics; 2015; 7(4):641-52. PubMed ID: 26111034
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic Strategies to Boost Cancer Immunotherapies.
Barrero MJ
Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28545238
[TBL] [Abstract][Full Text] [Related]
33. Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity.
Seliger B
Front Immunol; 2019; 10():999. PubMed ID: 31178856
[TBL] [Abstract][Full Text] [Related]
34. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy.
Tang T; Huang X; Zhang G; Hong Z; Bai X; Liang T
Signal Transduct Target Ther; 2021 Feb; 6(1):72. PubMed ID: 33608497
[TBL] [Abstract][Full Text] [Related]
35. What nature has to offer: Opportunities for immuno-oncology.
Kousar R; Lin CH; Patrick B; He M; Wu DC; Li XG
J Food Drug Anal; 2023 Jun; 31(2):212-231. PubMed ID: 37335163
[TBL] [Abstract][Full Text] [Related]
36. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy.
Li X; Shao C; Shi Y; Han W
J Hematol Oncol; 2018 Feb; 11(1):31. PubMed ID: 29482595
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors.
Perrier A; Didelot A; Laurent-Puig P; Blons H; Garinet S
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32708698
[TBL] [Abstract][Full Text] [Related]
38. The Contribution of Epigenetics to Cancer Immunotherapy.
Villanueva L; Álvarez-Errico D; Esteller M
Trends Immunol; 2020 Aug; 41(8):676-691. PubMed ID: 32622854
[TBL] [Abstract][Full Text] [Related]
39. The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves.
Kerr WG; Chisholm JD
J Immunol; 2019 Jan; 202(1):11-19. PubMed ID: 30587569
[TBL] [Abstract][Full Text] [Related]
40. H3K4 trimethylation regulates cancer immunity: a promising therapeutic target in combination with immunotherapy.
Xiao C; Fan T; Zheng Y; Tian H; Deng Z; Liu J; Li C; He J
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37553181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]